US FDA declines to approve Aldeyra's drug for eye disorder
17/03/2026 12:33
March 17 (Reuters) - The U.S. Food and Drug Administration on Tuesday declined to approve Aldeyra Therapeutics' ALDX.O drug for a type of eye disease, the company said. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sherry Jacob-Phillips) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease
Aldeyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aldeyra Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora